Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jul 26;14(7):e27315.
doi: 10.7759/cureus.27315. eCollection 2022 Jul.

Acquired Amegakaryocytic Thrombocytopenia Associated With Autoimmune Hemolytic Anemia

Naoto Ikeda  1 , Yuki Hisano  1 , Takayuki Kamao  1 , Masatoshi Uno  1 , Takaaki Mizushima  1
Affiliations
Case Reports

Acquired Amegakaryocytic Thrombocytopenia Associated With Autoimmune Hemolytic Anemia

Naoto Ikeda et al. Cureus. .

Abstract

Acquired amegakaryocytic thrombocytopenia (AATP) is a thrombocytopenic disorder characterized by a decrease in megakaryocytes in the bone marrow. AATP is effectively treated with immunosuppressive therapy. We report a case of a 68-years-old male referred to us due to purpuric lesions on the extremities and was noted to be thrombocytopenic. Bone marrow biopsy showed AATP with autoimmune hemolytic anemia (AIHA). Only two cases of AATP associated with AIHA have been reported. AATP should be differentiated carefully from other causes of peripheral destruction of platelets, such as immune thrombocytopenia (ITP).

Keywords: amegakaryocytic thrombocytopenia; autoimmune disease; autoimmune hemolytic anemia; thrombocytepenia; thrombopoietin.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Bone marrow smear on the day of admission showed no megakaryocytes (A, B). A megakaryocyte appeared on the seventh day of admission (C, D) (May-Giemsa staining).
Figure 2
Figure 2. Bone marrow biopsy images before (A) and after (B) treatment. After treatment, the megakaryocyte appearance was observed (arrow) (×400, hematoxylin-eosin staining).
Figure 3
Figure 3. The platelet count increased to 39,000/μL on the 16th day of admission.
PSL: Prednisolone, PC: Platelet Concentration
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Characteristics, management and outcome of acquired amegakaryocytic thrombocytopenia. Roeser A, Moulis G, Ebbo M, et al. Br J Haematol. 2022 - PubMed
    1. Acquired amegakaryocytic thrombocytopenic purpura. Agarwal N, Spahr JE, Werner TL, Newton DL, Rodgers GM. Am J Hematol. 2006;81:132–135. - PubMed
    1. Marked rebound thrombocytosis in response to glucocorticoids in a patient with acquired amegakaryocytic thrombocytopenia. Nishino S, Kodaka T, Sawada Y, Goka T, Gotoh Y, Tsunemine H, Takahashi T. J Clin Exp Hematop. 2018;58:166–170. - PMC - PubMed
    1. Acquired amegakaryocytic thrombocytopenia misdiagnosed as immune thrombocytopenia: a case report. Roy AM, Konda M, Sidarous GK, Atwal D, Schichman SA, Kunthur A. Perm J. 2020;24:1–3. - PMC - PubMed
    1. Acquired amegakaryocytic thrombocytopenic purpura treated with intravenous immunoglobulins. El Omri H, Skouri H, Kraiem I, et al. https://europepmc.org/article/med/10896976. Ann Med Interne (Paris) 2000;151:223–226. - PubMed

Publication types

LinkOut - more resources